World stocks are mixed follow Wall Street’s mostly positive performance ahead of key U.S. inflation data that could influence ...

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Inflation data this week has come in below forecasts. Earnings season is off to a solid start. Is this the medicine the ...

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales ...

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...